Du, Peter P.

Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade

Ishizuka, J. J., Manguso, R. T., Cheruiyot, C. K., Bi, K., Panda, A., Iracheta-Vellve, A., Miller, B. C., Du, P. P., Yates, K. B., Dubrot, J., et al. (2019) · Nature

Cancer Immunotherapy and BiomarkersRNA regulation and disease

Cited by 697

Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity

Griffin, G. K., Wu, J., Iracheta-Vellve, A., Patti, J. C., Hsu, J., Davis, T., Dele-Oni, D., Du, P. P., Halawi, A. G., Ishizuka, J. J., et al. (2021) · Nature

Cancer Immunotherapy and BiomarkersEpigenetics and DNA Methylation

Cited by 370

In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer

Dubrot, J., Du, P. P., Lane-Reticker, S. K., Kessler, E. A., Muscato, A. J., Mehta, A., Freeman, S. S., Allen, P. M., Olander, K. E., Ockerman, K. M., et al. (2022) · Nature Immunology

Cancer Immunotherapy and BiomarkersImmune Cell Function and Interaction

Cited by 218

Targeting TBK1 to overcome resistance to cancer immunotherapy

Sun, Y., Revach, O.-Y., Anderson, S., Kessler, E. A., Wolfe, C. H., Jenney, A., Mills, C. E., Robitschek, E. J., Davis, T. G. R., Kim, S., et al. (2023) · Nature

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 174

Development of compact transcriptional effectors using high-throughput measurements in diverse contexts

Tycko, J., Van, M. V., Aradhana, DelRosso, N., Ye, H., Yao, D., Valbuena, R., Vaughan-Jackson, A., Xu, X., Ludwig, C., et al. (2025) · Nature Biotechnology

CRISPR and Genetic EngineeringGenomics and Chromatin Dynamics

Cited by 57